查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1926853

無囊輸液袋市場按產品類型、材料、應用、最終用戶和分銷管道分類－2026-2032年全球預測

Bladderless Infusion Bag Market by Product Type, Material, Application, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年無囊輸液袋市值為 5.3021 億美元，預計到 2026 年將成長至 5.7604 億美元，預計到 2032 年將達到 9.4521 億美元，複合年成長率為 8.60%。

關鍵市場統計數據
基準年 2025 5.3021億美元
預計年份：2026年 5.7604億美元
預測年份 2032 9.4521億美元
複合年成長率 (%) 8.60%

關於無囊輸液袋技術、臨床意義和採購因素的權威框架為策略決策奠定了基礎。

無囊輸液袋的出現，已成為靜脈輸液領域的突破性創新，重塑了醫療機構的供應鏈、臨床實踐和設備選擇標準。這些產品優先考慮減少塑膠廢棄物，並與現代輸液通訊協定相容，同時提供替代材料配置，以解決人們對聚氯乙烯（PVC）基輸液系統日益成長的擔憂。隨著醫院和門診醫療機構在永續性目標和預算緊張的壓力下重新評估其採購重點，無囊輸液袋的評估標準不僅包括臨床適用性，還包括其生命週期環境影響和運作效率。

臨床、材料和採購趨勢的綜合作用正在推動輸液袋技術的策略轉變，並重塑其應用路徑。

臨床實務、材料創新和監管等多種因素的共同作用，正在重塑無囊輸液袋的市場格局。聚合物科學的進步拓展了非PVC替代品的選擇範圍，並推動產品重新設計，以滿足患者安全、化學相容性和永續性的需求。同時，醫療系統正在調整服務模式，轉向更便捷的門診/流動治療模式，這使得操作簡便、穩定性好、處置限制少的輸液產品顯得尤為重要。

2025年將改變美國供應鏈籌資策略、庫存計畫和定價結構的進口關稅和海關趨勢

2025年美國關稅趨勢為無囊輸液袋的製造商和經銷商帶來了複雜的商業性和營運挑戰。進口關稅和歸類規則的變化可能會影響原料（尤其是聚合物和添加劑）的採購決策，並改變海外生產與國內生產的比較優勢。對於擁有垂直整合供應鏈的公司而言，關稅波動可能促使它們在本地在地採購零件、實現供應商多元化，並重新評估合約條款，以保護利潤率並確保持續向美國醫療保健客戶供貨。

一個細緻、細分化的觀點，整合了產品設計、材料選擇、臨床應用案例、護理環境和通路，並與市場推廣促進因素保持一致。

要了解市場動態，需要對產品、材料、臨床應用、終端用戶環境和通路有清晰的認知。產品架構至關重要：從雙腔配置到單腔和三腔系統，各種選擇應有盡有，每種配置在劑量柔軟性、混合便利性和儲存特性方面都各有不同，這些都會影響臨床醫生的偏好和採購選擇。材料成分同樣重要。產品大致可以其是否使用非PVC替代品或傳統PVC系統進行分類，即使在非PVC產品中，也會根據乙烯-醋酸乙烯酯共聚物和聚乙烯混合物的不同而進一步區分，這些混合物對化學相容性、生產過程和環境影響各不相同。

區域分析描繪了全球主要市場叢集的採購行為、監管多樣性和臨床應用途徑

區域環境影響無囊輸液袋的監管要求、採購行動和臨床應用時間表。在美洲，負責人在成本控制和永續性舉措之間尋求平衡，這受到大規模綜合醫療網路的影響，這些網路整合了採購力量，並實現了各醫療機構設備選擇的標準化。這些趨勢有利於那些能夠證明其擁有嚴格的品質系統、穩定的供應保障以及在不影響臨床療效的前提下展現出環境效益的供應商。

一份深入的競爭評估報告，展示了產品創新、臨床夥伴關係和穩健的分銷模式如何創造永續的差異化優勢。

無囊輸液袋生態系統的競爭主要由材料和製造技術的創新、與臨床網路的策略合作以及確保供應連續性的能力所驅動。領先的製造商優先投資研發，以最佳化聚合物配方，使其既滿足臨床相容性要求，又能降低環境影響，並不斷改進生產流程，以支持大規模生產並提高成本效益。相關人員的合作是產品推廣應用的關鍵。那些資助同儕審查證據、真實世界應用研究和培訓計畫的供應商，通常能夠更順利地獲得醫院批准，並更快地被列入藥品目錄。

製造商和經銷商應採取具體措施，確保臨床應用，提高供應韌性，並使商業模式與當地採購優先事項保持一致。

為了將技術優勢轉化為持續的臨床應用，產業領導者必須在產品開發、供應鏈韌性和相關人員參與等方面採取果斷行動。投資於能夠降低環境影響、同時又能證明化學相容性和患者安全性的材料研究，優先進行檢驗研究，並建立透明的材料文檔，將有助於加快臨床認可和採購核准。同時，實現採購多元化，探索本地生產和契約製造，可以降低關稅波動和物流中斷帶來的風險，並為關鍵客戶提供更穩定的價格和更快的交貨速度。

採用透明的多學科方法，結合臨床醫生訪談、監管分析和技術審查，得出可操作的結論和建議。

本研究結合了臨床相關人員、採購負責人和供應鏈經理的訪談，並輔以對監管指南、生產實務和材料科學文獻的二次分析。這種方法平衡了來自臨床終端使用者和營運領導者的定性見解與聚合物性能和設備配置選項的技術審查。這種資訊來源的三角驗證，能夠提供反映住院、門診和診所實際運作的見解，確保策略建議既有文獻證據支持，也有實務經驗支撐。

清楚地總結了各項策略要務，闡明了臨床證據、供應可靠性和區域一致性如何決定產品的採納和長期價值。

無囊輸液袋代表材料科學、臨床實踐和供應鏈策略交叉領域的轉折點，它將影響醫療設備的採用和長期採購決策。雖然這項技術在某些醫療環境中具有顯著優勢，尤其是在環境影響、易用性和與門診護理流程的兼容性是優先考慮因素的情況下，但其成功應用將取決於明確的臨床等效性證據、可靠的供應保障以及與當地監管要求的契合度。那些投資於完善的檢驗、在地化供應鏈和有針對性的教育舉措的相關人員，將更有利於把產品創新轉化為可重複的臨床應用。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 無囊輸液袋市場（依產品類型分類）

  • 雙室
  • 單室
  • 三腔體

9. 無囊輸液袋市場（依材料分類）

  • 非氯乙烯
    • 乙烯-醋酸乙烯酯
    • 聚乙烯
  • 聚氯乙烯

第10章 無囊輸液袋市場依應用領域分類

  • 輸血
  • 化療
  • 水合作用
  • 靜脈營養

第11章 無囊輸液袋市場（以最終用戶分類）

  • 門診治療
  • 診所
  • 醫院

第12章 無囊輸液袋市場（依通路分類）

  • 批發商
  • 醫院藥房
  • 網路藥房

第13章 各地區無囊輸液袋市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 無囊輸液袋市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國無囊輸液袋市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國無囊輸液袋市場

第17章 中國無囊輸液袋市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • B. Braun
  • Baxter International
  • Fresenius Kabi
  • Grifols SA
  • Huaren Pharmaceutical Co. Ltd.
  • JW Life Science Corp.
  • Merck Millipore
  • PolyCine GmbH
  • Sealed Air Corp.
  • Sichuan Kelun Pharmaceutical
  • Technoflex SAS
  • Terumo Corporation
  • Wipak Walsrode GmbH
Product Code: MRR-4F7A6D4FF336

The Bladderless Infusion Bag Market was valued at USD 530.21 million in 2025 and is projected to grow to USD 576.04 million in 2026, with a CAGR of 8.60%, reaching USD 945.21 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 530.21 million
Estimated Year [2026] USD 576.04 million
Forecast Year [2032] USD 945.21 million
CAGR (%) 8.60%

An authoritative framing of bladderless infusion bag technologies, clinical relevance, and procurement drivers that set the stage for strategic decision-making

Bladderless infusion bags have emerged as a pivotal innovation within intravenous therapy delivery, reshaping supply chains, clinical practice, and device selection criteria across care settings. These products prioritize reduced plastic waste profiles and compatibility with contemporary infusion protocols while offering alternative material compositions that respond to escalating concerns about polyvinyl chloride-based systems. As hospitals and outpatient providers reassess procurement priorities under pressure from sustainability goals and tighter budgetary constraints, bladderless infusion bags are increasingly evaluated not only for clinical compatibility but also for lifecycle environmental impact and operational efficiencies.

This analysis frames bladderless infusion technologies in the context of their material science, configuration options, and clinical applications. It situates these devices within evolving regulatory expectations and procurement behaviors, underscoring how technical design choices influence handling, storage, and compatibility with existing infusion pumps and workflows. Moreover, the section highlights how service providers and distributors are adapting stocking strategies and inventory models to support widespread adoption while mitigating risk in sterile supply chains. By clarifying the core attributes and system requirements of bladderless infusion bags, this introduction establishes the foundation for deeper insight into market dynamics, regional nuances, and strategic imperatives for manufacturers, suppliers, and clinical leaders.

A synthesis of clinical, material, and procurement dynamics that are driving strategic shifts and reshaping adoption pathways for infusion bag technologies

The landscape for bladderless infusion bags is being reshaped by converging forces in clinical practice, material innovation, and regulatory scrutiny. Advances in polymer science have expanded viable non-PVC alternatives, catalyzing product redesigns that address patient safety, chemical compatibility, and sustainability expectations. At the same time, healthcare systems are reengineering care delivery toward more ambulatory and outpatient models, thereby elevating the importance of infusion products that offer simplified handling, robust storage stability, and fewer disposal constraints.

Shifts in procurement philosophies are also materializing: value assessment is moving beyond unit price to include total cost of ownership, environmental impact, and ease of integration into existing clinical protocols. This transition encourages suppliers to present comprehensive value propositions that bundle training, supply continuity guarantees, and compatibility assurances. Additionally, heightened regulatory emphasis on traceability and supply chain transparency is prompting manufacturers to invest in serialization, enhanced quality systems, and documentation to facilitate hospital credentialing and audit processes.

Taken together, these transformative trends are driving product differentiation along dimensions that matter most to clinicians and supply chain managers: material safety, clinical performance, environmental footprint, and assurance of supply continuity. As adoption pathways evolve, stakeholders who anticipate interoperability challenges and articulate clear evidence of clinical equivalence will be best positioned to translate innovation into routine use

How changes in import duties and customs practices are altering sourcing strategies, inventory planning, and pricing structures for U.S. supply chains in 2025

Tariff developments in the United States for 2025 introduce a complex layer of commercial and operational considerations for manufacturers and distributors of bladderless infusion bags. Changes to import duties and classification rules can influence sourcing decisions for raw materials, particularly polymers and additives, and may alter the comparative advantage of offshore versus domestic production. For companies with vertically integrated supply chains, tariff shifts create incentives to reexamine component localization, supplier diversification, and contract terms to protect margins and ensure uninterrupted supply to U.S. healthcare customers.

Moreover, tariff-related adjustments can affect inventory strategies; stakeholders may elect to increase buffer stocks or accelerate procurement to hedge against cost volatility, which in turn impacts warehousing needs and working capital. Payers and health systems, seeking predictable procurement costs, may push for longer contract terms or fixed-price agreements, prompting suppliers to incorporate tariff risk clauses or hedging mechanisms into their commercial models. Regulatory compliance and customs classification clarity become essential operational priorities to avoid unexpected duties and mitigate the risk of delayed clearances at ports of entry.

In response, many organizations are evaluating nearshoring and regional manufacturing partnerships to reduce exposure to tariff oscillations while improving lead times and quality control. Transparent communication with purchasing groups and supply chain partners, coupled with scenario planning for duty changes, will be critical to sustaining supply reliability and preserving competitive pricing structures in the U.S. clinical market

A nuanced segmentation-driven perspective that aligns product design, material selection, clinical use cases, care settings, and distribution channels with adoption levers

Understanding market dynamics requires a clear view of product, material, clinical application, end-user contexts, and distribution pathways. Product architecture matters: options range from double chamber configurations to single chamber and triple chamber systems, each offering different dosing flexibility, admixture convenience, and storage characteristics that influence clinician preference and procurement selection. Material composition is equally consequential; products are broadly categorized by their use of non-polyvinyl chloride alternatives versus traditional polyvinyl chloride systems, and among non-PVC choices there is further differentiation between ethylene vinyl acetate and polyethylene formulations, which carry distinct implications for chemical compatibility, manufacturing processes, and environmental profile.

Clinical application drives specification and adoption; bladderless systems are evaluated across blood transfusion, chemotherapy, hydration therapy, and parenteral nutrition use cases, where fluid compatibility, sterility assurance, and administration accuracy are paramount. The setting of care shapes operational requirements: ambulatory care sites favor compact, easy-to-handle formats that reduce disposal burden, clinics prioritize reusable compatibility with existing infusion technologies, and hospitals demand high throughput solutions that support efficient stocking and rapid deployment during complex procedures. Distribution channels determine availability and procurement dynamics; distributors play a central role in logistics and contract facilitation, hospital pharmacies manage clinical stocking and stewardship, and online pharmacies present an emerging channel for outpatient and home infusion access. By integrating these segmentation lenses, stakeholders can align product development and commercial strategies with the specific needs of each clinical and supply chain cohort

A regionally informed analysis that maps procurement behaviors, regulatory diversity, and clinical adoption vectors across major global market clusters

Regional context shapes regulatory expectations, procurement behaviors, and clinical adoption timelines for bladderless infusion bags. In the Americas, purchasers are balancing cost containment with sustainability initiatives and are influenced by large integrated delivery networks that consolidate purchasing power and standardize device selection across facilities. These dynamics favor suppliers that can demonstrate rigorous quality systems, robust supply continuity, and evidence of environmental benefits without compromising clinical performance.

Across Europe, the Middle East & Africa, regulatory diversity and varying reimbursement mechanisms produce heterogenous adoption patterns. In several European markets, policy drivers and hospital sustainability targets accelerate interest in non-PVC solutions, while in other markets procurement cycles and budgetary constraints can slow uptake. Middle Eastern and African healthcare systems often prioritize scalable, cost-effective options that can be integrated into centralized procurement frameworks, creating opportunities for regional distributors and manufacturers that can provide localized service and training.

Asia-Pacific presents a mixed picture with advanced tertiary centers in some countries adopting novel infusion technologies rapidly, while other markets prioritize cost and local manufacturing capacity. In fast-growing outpatient and home infusion segments, Asia-Pacific providers are especially sensitive to ease of use, storage stability in diverse climates, and alignment with evolving clinical protocols. Across all regions, successful commercialization requires tailored regulatory strategies, localized value messaging, and supply chain models that address regional logistics and procurement norms

An incisive assessment of competitive strategies showing how product innovation, clinical partnerships, and resilient distribution models create sustainable differentiation

Competitive dynamics within the bladderless infusion bag ecosystem are shaped by innovation in materials and manufacturing, strategic partnerships with clinical networks, and the ability to guarantee supply continuity. Leading manufacturers are prioritizing R&D investments that optimize polymer formulations to meet clinical compatibility requirements while reducing environmental impact, and they are refining production processes to support high-volume, cost-efficient output. Collaboration with clinical stakeholders is central to adoption; suppliers that fund peer-reviewed evidence, real-world use studies, and training programs typically see smoother hospital credentialing and faster inclusion in formularies.

Distribution and service models are evolving in parallel, with an increasing emphasis on value-added services such as inventory management, just-in-time delivery, and digital tools that enable traceability and usage analytics. Companies that can offer integrated solutions-combining product reliability with predictable logistics and actionable data-create differentiation in procurement conversations. Similarly, manufacturers pursuing regional manufacturing footprints or contract manufacturing arrangements are better positioned to mitigate tariff and transportation risks while meeting localized regulatory requirements. Overall, the competitive landscape rewards firms that balance technical excellence, operational resilience, and collaborative commercialization strategies with healthcare providers

Targeted actions for manufacturers and distributors to secure clinical adoption, improve supply resilience, and align commercial models with regional procurement priorities

Industry leaders should act decisively across product development, supply chain resilience, and stakeholder engagement to convert technical advantages into sustained clinical adoption. Invest in material research that demonstrates chemical compatibility and patient safety while enabling a lower environmental footprint; prioritized validation studies and transparent materials documentation will expedite clinical acceptance and procurement approval. Concurrently, diversify sourcing and explore regional production or contract manufacturing to reduce exposure to tariff fluctuations and logistics disruptions, enabling more stable pricing and shorter lead times for critical customers.

Engage early with clinical champions and procurement groups to co-design training, handling protocols, and inventory management workflows that minimize implementation friction. Offer bundled solutions that include demonstrable supply continuity commitments, education resources, and access to usage analytics to support hospital stewardship programs. Finally, tailor commercial approaches by region and care setting-align messaging with sustainability priorities in markets that emphasize environmental impact, emphasize ease of use in ambulatory and home infusion segments, and underscore cost predictability for large integrated health systems. These actions, taken together, will enhance market receptivity and support long-term partnerships with care providers

A transparent, mixed-methods approach combining clinician interviews, regulatory analysis, and technical review to underpin actionable insights and recommendations

This research synthesizes primary interviews with clinical stakeholders, procurement professionals, and supply chain managers, complemented by secondary analysis of regulatory guidance, manufacturing practices, and material science literature. The approach balances qualitative insight from clinician end users and operations leaders with technical review of polymer characteristics and device configuration options. Triangulation of sources ensures that findings reflect operational realities across inpatient, clinic, and ambulatory care environments, and that strategic recommendations are grounded in both documented evidence and practitioner experience.

Data integrity was maintained through cross-validation of interview themes with publicly available regulatory documents and manufacturer technical specifications, and by assessing distribution channel behaviors through conversations with logistics providers and hospital pharmacy leaders. Regional analyses incorporated policy review and stakeholder feedback to capture differences in procurement cycles and regulatory pathways. Throughout the methodology, emphasis was placed on capturing actionable intelligence for commercial and clinical decision-makers while avoiding speculative projections. The synthesis prioritizes transparency in source attribution and methodological rigor to support confident implementation of the insights presented

A clear synthesis of strategic imperatives showing how clinical evidence, supply reliability, and regional alignment determine adoption and long-term value

Bladderless infusion bags represent an inflection point where material science, clinical practice, and supply chain strategy intersect to influence device adoption and long-term procurement decisions. The technology offers tangible advantages in certain care contexts-particularly where environmental impact, ease of handling, and compatibility with ambulatory workflows are prioritized-but successful adoption hinges on clear evidence of clinical equivalence, demonstrated supply reliability, and alignment with regional regulatory expectations. Stakeholders that invest in robust validation, localized supply arrangements, and targeted education initiatives will be best placed to translate product innovation into repeatable clinical use.

Moving forward, the most effective commercialization strategies will combine technical credibility with operational assurance. Manufacturers and distributors that deliver consistent quality, partner with clinical leaders to generate real-world evidence, and structure distribution to minimize disruption will create durable advantages in competitive procurement environments. For healthcare providers and procurement organizations, the choice to adopt bladderless infusion systems should be informed by comparative assessments of material compatibility, lifecycle implications, and the provider's capacity to integrate new device workflows without compromising patient safety or operational efficiency. Taken together, the insights in this report aim to equip decision-makers with the context needed to navigate adoption thoughtfully and pragmatically

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Bladderless Infusion Bag Market, by Product Type

  • 8.1. Double Chamber
  • 8.2. Single Chamber
  • 8.3. Triple Chamber

9. Bladderless Infusion Bag Market, by Material

  • 9.1. Non Polyvinyl Chloride
    • 9.1.1. Ethylene Vinyl Acetate
    • 9.1.2. Polyethylene
  • 9.2. Polyvinyl Chloride

10. Bladderless Infusion Bag Market, by Application

  • 10.1. Blood Transfusion
  • 10.2. Chemotherapy
  • 10.3. Hydration
  • 10.4. Parenteral Nutrition

11. Bladderless Infusion Bag Market, by End User

  • 11.1. Ambulatory Care
  • 11.2. Clinics
  • 11.3. Hospitals

12. Bladderless Infusion Bag Market, by Distribution Channel

  • 12.1. Distributors
  • 12.2. Hospital Pharmacies
  • 12.3. Online Pharmacies

13. Bladderless Infusion Bag Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Bladderless Infusion Bag Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Bladderless Infusion Bag Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Bladderless Infusion Bag Market

17. China Bladderless Infusion Bag Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. B. Braun
  • 18.6. Baxter International
  • 18.7. Fresenius Kabi
  • 18.8. Grifols S.A.
  • 18.9. Huaren Pharmaceutical Co. Ltd.
  • 18.10. JW Life Science Corp.
  • 18.11. Merck Millipore
  • 18.12. PolyCine GmbH
  • 18.13. Sealed Air Corp.
  • 18.14. Sichuan Kelun Pharmaceutical
  • 18.15. Technoflex SAS
  • 18.16. Terumo Corporation
  • 18.17. Wipak Walsrode GmbH

LIST OF FIGURES

  • FIGURE 1. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BLADDERLESS INFUSION BAG MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BLADDERLESS INFUSION BAG MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY MATERIAL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES BLADDERLESS INFUSION BAG MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA BLADDERLESS INFUSION BAG MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY DOUBLE CHAMBER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY DOUBLE CHAMBER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY DOUBLE CHAMBER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY SINGLE CHAMBER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY SINGLE CHAMBER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY SINGLE CHAMBER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY TRIPLE CHAMBER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY TRIPLE CHAMBER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY TRIPLE CHAMBER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY NON POLYVINYL CHLORIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY NON POLYVINYL CHLORIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY NON POLYVINYL CHLORIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY NON POLYVINYL CHLORIDE, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY ETHYLENE VINYL ACETATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY ETHYLENE VINYL ACETATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY ETHYLENE VINYL ACETATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY POLYETHYLENE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY POLYETHYLENE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY POLYETHYLENE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY POLYVINYL CHLORIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY POLYVINYL CHLORIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY POLYVINYL CHLORIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY BLOOD TRANSFUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY BLOOD TRANSFUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY BLOOD TRANSFUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY HYDRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY HYDRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY HYDRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY PARENTERAL NUTRITION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY PARENTERAL NUTRITION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY PARENTERAL NUTRITION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY AMBULATORY CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY AMBULATORY CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY AMBULATORY CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY DISTRIBUTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY DISTRIBUTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY DISTRIBUTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS BLADDERLESS INFUSION BAG MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 61. AMERICAS BLADDERLESS INFUSION BAG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 62. AMERICAS BLADDERLESS INFUSION BAG MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 63. AMERICAS BLADDERLESS INFUSION BAG MARKET SIZE, BY NON POLYVINYL CHLORIDE, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS BLADDERLESS INFUSION BAG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS BLADDERLESS INFUSION BAG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS BLADDERLESS INFUSION BAG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA BLADDERLESS INFUSION BAG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. NORTH AMERICA BLADDERLESS INFUSION BAG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 69. NORTH AMERICA BLADDERLESS INFUSION BAG MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA BLADDERLESS INFUSION BAG MARKET SIZE, BY NON POLYVINYL CHLORIDE, 2018-2032 (USD MILLION)
  • TABLE 71. NORTH AMERICA BLADDERLESS INFUSION BAG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA BLADDERLESS INFUSION BAG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA BLADDERLESS INFUSION BAG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 74. LATIN AMERICA BLADDERLESS INFUSION BAG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. LATIN AMERICA BLADDERLESS INFUSION BAG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. LATIN AMERICA BLADDERLESS INFUSION BAG MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA BLADDERLESS INFUSION BAG MARKET SIZE, BY NON POLYVINYL CHLORIDE, 2018-2032 (USD MILLION)
  • TABLE 78. LATIN AMERICA BLADDERLESS INFUSION BAG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 79. LATIN AMERICA BLADDERLESS INFUSION BAG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA BLADDERLESS INFUSION BAG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA BLADDERLESS INFUSION BAG MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA BLADDERLESS INFUSION BAG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA BLADDERLESS INFUSION BAG MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA BLADDERLESS INFUSION BAG MARKET SIZE, BY NON POLYVINYL CHLORIDE, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA BLADDERLESS INFUSION BAG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA BLADDERLESS INFUSION BAG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA BLADDERLESS INFUSION BAG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE BLADDERLESS INFUSION BAG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE BLADDERLESS INFUSION BAG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE BLADDERLESS INFUSION BAG MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE BLADDERLESS INFUSION BAG MARKET SIZE, BY NON POLYVINYL CHLORIDE, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE BLADDERLESS INFUSION BAG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE BLADDERLESS INFUSION BAG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE BLADDERLESS INFUSION BAG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 95. MIDDLE EAST BLADDERLESS INFUSION BAG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. MIDDLE EAST BLADDERLESS INFUSION BAG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. MIDDLE EAST BLADDERLESS INFUSION BAG MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 98. MIDDLE EAST BLADDERLESS INFUSION BAG MARKET SIZE, BY NON POLYVINYL CHLORIDE, 2018-2032 (USD MILLION)
  • TABLE 99. MIDDLE EAST BLADDERLESS INFUSION BAG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 100. MIDDLE EAST BLADDERLESS INFUSION BAG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST BLADDERLESS INFUSION BAG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 102. AFRICA BLADDERLESS INFUSION BAG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. AFRICA BLADDERLESS INFUSION BAG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. AFRICA BLADDERLESS INFUSION BAG MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 105. AFRICA BLADDERLESS INFUSION BAG MARKET SIZE, BY NON POLYVINYL CHLORIDE, 2018-2032 (USD MILLION)
  • TABLE 106. AFRICA BLADDERLESS INFUSION BAG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 107. AFRICA BLADDERLESS INFUSION BAG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. AFRICA BLADDERLESS INFUSION BAG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC BLADDERLESS INFUSION BAG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC BLADDERLESS INFUSION BAG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC BLADDERLESS INFUSION BAG MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC BLADDERLESS INFUSION BAG MARKET SIZE, BY NON POLYVINYL CHLORIDE, 2018-2032 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC BLADDERLESS INFUSION BAG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC BLADDERLESS INFUSION BAG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC BLADDERLESS INFUSION BAG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. ASEAN BLADDERLESS INFUSION BAG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. ASEAN BLADDERLESS INFUSION BAG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. ASEAN BLADDERLESS INFUSION BAG MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 120. ASEAN BLADDERLESS INFUSION BAG MARKET SIZE, BY NON POLYVINYL CHLORIDE, 2018-2032 (USD MILLION)
  • TABLE 121. ASEAN BLADDERLESS INFUSION BAG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 122. ASEAN BLADDERLESS INFUSION BAG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. ASEAN BLADDERLESS INFUSION BAG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 124. GCC BLADDERLESS INFUSION BAG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GCC BLADDERLESS INFUSION BAG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. GCC BLADDERLESS INFUSION BAG MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 127. GCC BLADDERLESS INFUSION BAG MARKET SIZE, BY NON POLYVINYL CHLORIDE, 2018-2032 (USD MILLION)
  • TABLE 128. GCC BLADDERLESS INFUSION BAG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 129. GCC BLADDERLESS INFUSION BAG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. GCC BLADDERLESS INFUSION BAG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPEAN UNION BLADDERLESS INFUSION BAG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPEAN UNION BLADDERLESS INFUSION BAG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPEAN UNION BLADDERLESS INFUSION BAG MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPEAN UNION BLADDERLESS INFUSION BAG MARKET SIZE, BY NON POLYVINYL CHLORIDE, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPEAN UNION BLADDERLESS INFUSION BAG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPEAN UNION BLADDERLESS INFUSION BAG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPEAN UNION BLADDERLESS INFUSION BAG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 138. BRICS BLADDERLESS INFUSION BAG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. BRICS BLADDERLESS INFUSION BAG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. BRICS BLADDERLESS INFUSION BAG MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 141. BRICS BLADDERLESS INFUSION BAG MARKET SIZE, BY NON POLYVINYL CHLORIDE, 2018-2032 (USD MILLION)
  • TABLE 142. BRICS BLADDERLESS INFUSION BAG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 143. BRICS BLADDERLESS INFUSION BAG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. BRICS BLADDERLESS INFUSION BAG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 145. G7 BLADDERLESS INFUSION BAG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. G7 BLADDERLESS INFUSION BAG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. G7 BLADDERLESS INFUSION BAG MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 148. G7 BLADDERLESS INFUSION BAG MARKET SIZE, BY NON POLYVINYL CHLORIDE, 2018-2032 (USD MILLION)
  • TABLE 149. G7 BLADDERLESS INFUSION BAG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 150. G7 BLADDERLESS INFUSION BAG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. G7 BLADDERLESS INFUSION BAG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 152. NATO BLADDERLESS INFUSION BAG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. NATO BLADDERLESS INFUSION BAG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. NATO BLADDERLESS INFUSION BAG MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 155. NATO BLADDERLESS INFUSION BAG MARKET SIZE, BY NON POLYVINYL CHLORIDE, 2018-2032 (USD MILLION)
  • TABLE 156. NATO BLADDERLESS INFUSION BAG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 157. NATO BLADDERLESS INFUSION BAG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. NATO BLADDERLESS INFUSION BAG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. UNITED STATES BLADDERLESS INFUSION BAG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 161. UNITED STATES BLADDERLESS INFUSION BAG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. UNITED STATES BLADDERLESS INFUSION BAG MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 163. UNITED STATES BLADDERLESS INFUSION BAG MARKET SIZE, BY NON POLYVINYL CHLORIDE, 2018-2032 (USD MILLION)
  • TABLE 164. UNITED STATES BLADDERLESS INFUSION BAG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 165. UNITED STATES BLADDERLESS INFUSION BAG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 166. UNITED STATES BLADDERLESS INFUSION BAG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 167. CHINA BLADDERLESS INFUSION BAG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 168. CHINA BLADDERLESS INFUSION BAG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. CHINA BLADDERLESS INFUSION BAG MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 170. CHINA BLADDERLESS INFUSION BAG MARKET SIZE, BY NON POLYVINYL CHLORIDE, 2018-2032 (USD MILLION)
  • TABLE 171. CHINA BLADDERLESS INFUSION BAG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 172. CHINA BLADDERLESS INFUSION BAG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. CHINA BLADDERLESS INFUSION BAG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)